Clinical trials: High-risk Patients
Heart Failure
Study to Collect High-Resolution ECG Data and Patient Insights on Heart Failure Care
The purpose of this study is to establish an electrocardiogram (ECG) data library to facilitate future studies on heart disease.
- Trial name
- NCT06809686
- Where
- 2 sites in United Kingdom
- Volunteers
- 1,000 people
- Sponsor
- Richmond Research Institute
Myelodysplastic Syndrome, Acute Myelogenous Leukemia
A Phase I/II Study of MGCD0103 With Azacitidine in Patients With High-Risk Myelodysplastic Syndrome (MDS) or Acute Myelogenous Leukemia
In this study, MGCD0103, a new anticancer drug under investigation, is given three times weekly in combination with azacitidine to patients with high-risk myelodysplastic syndromes or acute myelogenous leukemia.
- Trial name
- NCT00324220
- Testing
- MGCD0103
- Where
- 8 sites in United States
- Volunteers
- 66 people
- Sponsor
- Mirati Therapeutics Inc.
Hypercholesterolemia
Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Ezetimibe on Top of Statin in High Cardiovascular Risk Patients With Hypercholesterolemia (ODYSSEY COMBO II)
Alirocumab (SAR236553/REGN727) is a fully human monoclonal antibody that binds PCSK9 (proprotein convertase subtilisin/kexin type 9).
- Trial name
- NCT01644188
- Testing
- Alirocumab, Ezetimibe, Lipid Modifying Therapy (LMT)
- Where
- 126 sites in United States, Canada and 8 more
- Volunteers
- 720 people
- Sponsor
- Sanofi
Melanoma, Merkel Cell Carcinoma
High-Risk Skin Cancers With Atezolizumab Plus NT-I7
The purpose of this study is to test whether the addition of NT-I7 to atezolizumab provides clinically meaningful outcomes for patients with anti-PD-1/PD-L1 naive or relapsed/refractory high-risk melanoma, Merkel Cell Carcinoma…
- Conditions
- Melanoma, Merkel Cell Carcinoma, Cutaneous Squamous Cell Carcinoma
- Trial name
- NCT03901573
- Testing
- NT-I7, atezolizumab
- Where
- 8 sites in United States
- Volunteers
- 31 people
- Sponsor
- NeoImmuneTech
Clostridium Difficile Infection
Safety and Efficacy of DAV132 in Patients at High-Risk for Clostridium Difficile Infection (CDI)
The purpose of this study is to determine the safe use and evaluate the efficacy/performance of DAV132 in hospitalized patients at high risk for Clostridium difficile infection (CDI) and who receive fluoroquinolones (FQs) for the…
- Trial name
- SHIELD (NCT03710694)
- Testing
- DAV132
- Where
- 29 sites in Bulgaria, Germany and 2 more
- Volunteers
- 260 people
- Sponsor
- Da Volterra
Chronic Kidney Failure
Efficacy and Safety Study of Magnesium Iron Hydroxycarbonate for the Reduction of High Blood Phosphate in Hemodialysis Patients
Magnesium iron hydroxycarbonate is a phosphate binder that absorbs phosphate from food, reducing the amount that the body can absorb.
- Trial name
- NCT00317694
- Testing
- Fermagate
- Where
- 15 sites in United States, United Kingdom
- Volunteers
- 111 people
- Sponsor
- Ineos Healthcare Limited
Paroxysmal Nocturnal Hemoglobinuria, Natural History Study
Natural History Study of Adult Patients With Paroxysmal Nocturnal Hemoglobinuria of High-risk Hemolysis in China
This is a single-center observational study conducted in adult patients with paroxysmal nocturnal hemoglobinuria of high-risk hemolysis.
- Trial name
- NCT05125341
- Where
- China
- Volunteers
- 67 people
- Sponsor
- CARE Pharma Shanghai Ltd.
Dyslipidemia
Survey of Lipid Goal Attainment and Mortality in Patients With High Cardiovascular Risk in Thailand
The first phase of the study is a hospital-based cross-sectional, epidemiological survey. The required sample size is 1,260 patients from 50 hospitals across Thailand.
- Trial name
- NCT00684151
- Where
- 49 sites in Thailand
- Volunteers
- 1,240 people
- Sponsor
- AstraZeneca
Metastatic Melanoma
HD IL-2 + Vemurafenib in Patients With BRAF Mutation Positive Metastatic Melanoma
This is a research study to evaluate treatment of metastatic melanoma patients with a combination of drugs. The combination being studied is vemurafenib (also known as Zelboraf®) and High Dose Interleukin-2 (abbreviated as HD…
- Trial name
- PROCLIVITY01 (NCT01683188)
- Testing
- vemurafenib + HD IL-2
- Where
- 21 sites in United States
- Volunteers
- 53 people
- Sponsor
- Clinigen, Inc.
Acute Pancreatitis Without Necrosis or Infection
Combination of Cytokine Hemosorption and High-volume Hemofiltration in Acute Pancreatitis
Mortality from severe acute pancreatitis reaches 42%. The prognosis of acute pancreatitis is associated with the development of acute inflammatory response syndrome (SIRS) and multiple organ failure (MOF).
- Trial name
- NCT05694988
- Testing
- Efferon CT
- Where
- Russia
- Volunteers
- 28 people
- Sponsor
- Efferon JSC
High-grade Squamous Intraepithelial Lesion (HSIL)
Evaluation of NWRD08 for HPV-16 and/or HPV-18 Related Cervical HSIL
This is a randomized, double-blind, placebo controlled Phase 2 study to determine the efficacy and safety of NWRD08 administered by intramuscular (IM) injection followed by electroporation (EP) in adult women with histologically…
- Trial name
- NCT07175662
- Testing
- NWRD08 administered by electroporation
- Where
- 5 sites in China
- Volunteers
- 150 people
- Sponsor
- Newish Biotech (Wuxi) Co., Ltd.
Crohn's Disease
High Dose Oral 4-Aminosalicylic Acid (PASER®) to Control Acute Flares of Mild to Moderate Crohn's Disease
The purpose of this 4 week study is to determine whether PASER®, an approved delayed-release oral formulation of 4-aminosalicylic acid, in doses of 4 grams three times daily for 2 weeks followed by 4 grams twice daily for 2…
- Trial name
- NCT00417690
- Testing
- 4-Aminosalicylic acid
- Where
- 5 sites in United States, Israel
- Volunteers
- 54 people
- Sponsor
- Jacobus Pharmaceutical
Adult Patients in Need of High-energy Oral Nutritional Supplementation
Acceptability Study on Nutricomp® Drink Plus Fibre in Adults
Required for Advisory Committee for Borderline Substances (ACBS) approval. Aim of this study is to access the palatability, compliance and GI-tolerance of Nutricomp® Drink Plus Fibre to show that it is acceptable for patients in…
- Trial name
- Fuchsia (NCT03013803)
- Testing
- Nutricomp Drink Plus Fibre
- Where
- United Kingdom
- Volunteers
- 19 people
- Sponsor
- B. Braun Melsungen AG
Hypertension
High Dose BAYA1040_Nifedipine: a Dose-comparative Study
This is a clinical study evaluating the superiority in efficacy and assess safety and tolerability of BAYA1040_Nifedipine 80 mg/day (40 mg twice daily) compared with BAYA1040_Nifedipine 40 mg/day (40 mg once daily) in patients…
- Trial name
- NCT01287260
- Testing
- Nifedipine (Adalat, BAYA1040)
- Where
- 22 sites in Japan
- Volunteers
- 352 people
- Sponsor
- Bayer
Metastatic Melanoma
HD IL-2 + Ipilimumab in Patients With Metastatic Melanoma
Phase IV, open-label, randomized, two-arm, multi-center study in patients with metastatic melanoma who are treatment naïve or have previously received a single non-immunologic therapy.
- Trial name
- PROCLIVITY02 (NCT01856023)
- Testing
- High Dose Interleukin-2, Ipilimumab
- Where
- 12 sites in United States
- Volunteers
- 29 people
- Sponsor
- Clinigen, Inc.
Uterine Cervical Dysplasia
A Study of Amolimogene (ZYC101a) in Patients With High Grade Cervical Intraepithelial Lesions of the Uterine Cervix
The purpose of this study is to evaluate the efficacy and safety of amolimogene, in the treatment of patients with high-grade cervical intraepithelial lesions of the uterine cervix.
- Trial name
- NCT00264732
- Testing
- Amolimogene
- Where
- 26 sites in United States
- Volunteers
- 251 people
- Sponsor
- Eisai Inc.
Febrile Neutropenia, Non-myeloid Malignancy
An Analysis to Estimate Febrile Neutropenia (FN) in Patients Receiving Udenyca
This is a multicenter, prospective, observational cohort registry in subjects receiving myelosuppressive chemotherapy for a non-myeloid malignancy who are considered to be at high risk for developing febrile neutropenia (FN).
- Trial name
- POEM (NCT04662892)
- Testing
- Pegfilgrastim-Cbqv
- Where
- 3 sites in United States
- Volunteers
- 200 people
- Sponsor
- Coherus Oncology, Inc.
Hypertension
A Safety and Tolerability Study of the Combination of Aliskiren/Valsartan in Patients With High Blood Pressure, Followed by Long-term Safety and Tolerability of Aliskiren, Valsartan and Hydrochlorothiazide.
Assessment of the long-term safety and tolerability of the combination of aliskiren and valsartan (300 mg/ 320 mg) in patients with high blood pressure,followed by assessment of long-term safety and tolerability of the…
- Trial name
- NCT00386607
- Testing
- Aliskiren, Valsartan, Hydrochlorothiazide (HCTZ)
- Where
- 4 sites in United States, Canada and 2 more
- Volunteers
- 601 people
- Sponsor
- Novartis
Relapsed or Refractory Aggressive B-Cell Non-Hodgkins Lymphoma
Evaluate Optimization of CRS Profile for Glofit Monotherapy and Glofit+GemOx in R/R Aggressive B-NHL
This Phase II trial evaluates the optimization of the cytokine release syndrome (CRS) profile for glofitamab in combination with gemcitabine and oxaliplatin (Glofit-GemOx) followed by glofitamab monotherapy treatment regimen (Cohort…
- Trial name
- NCT06806033
- Testing
- Obinutuzumab, Glofitamab, Gemcitabine
- Where
- 53 sites in United States, Australia and 5 more
- Volunteers
- 130 people
- Sponsor
- Hoffmann-La Roche
Hypertension
Efficacy and Safety of Valsartan/Hydrochlorothiazide Combination Therapy in Patients With Hypertension
This is a double-blind study to evaluate the reduction in systolic blood pressure using a therapy initiated with valsartan 160 mg or valsartan + hydrochlorothiazide (HCTZ) 160/12.5 mg compared to a more conventional approach…
- Trial name
- NCT00280540
- Testing
- Valsartan/Hydrochlorothiazide
- Where
- United States
- Volunteers
- 648 people
- Sponsor
- Novartis
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.